Gabriel N. Hortobagyi, MD, FACP, FASCO, is the recipient of the 2018 Gianni Bonadonna Breast Cancer Award for his leadership and contribution in the field of translational medicine in breast cancer, with an exceptional record of mentorship.
The treatment paradigm of breast cancer has celebrated the successes of targeted therapy for decades. Currently, the hormone receptor and HER2 statuses of a breast tumor continue to drive the selection of therapy for patients with early-stage breast cancer and metastatic breast cancer (mBC).
Abemaciclib combined with the estrogen inhibitor fulvestrant may significantly reduce the risk of disease progression and increase the objective response rate in women with metastatic breast cancer, according to the results of the MONARCH 2 study.
Two studies presented during the 2017 ASCO Annual Meeting provided additional evidence of the efficacy and safety of the CDK4/6 inhibitor ribociclib plus letrozole as a first-line treatment for ER-positive/HER2-negative advanced breast cancer.
Consensus guidelines on the minimal necessary margin width in the setting of breast-conserving surgery margins have great potential to increase standardization of practice and reduce morbidity and cost; however, we must be careful not to fall into the trap of practicing “cookbook medicine.”
A large study found that the individual surgeon and the institution exert greater influence on whether patients undergo mastectomy versus lumpectomy compared with all other clinical and demographic variables, except for tumor size and nodal status.
Results from the phase III ETNA study concluded there was no statistical difference in the pCR rate between neoadjuvant nab-paclitaxel and paclitaxel both followed by anthracycline regimens in women with HER2-negative high-risk breast cancer.
Extending aromatase inhibitor therapy beyond the standard 5 years out to 10 years for postmenopausal women with HR-positive early breast cancer significantly improves disease-free survival over placebo.